URGN PE Ratio & Valuation,Is URGN Overvalued

URGN Relative Valuation

URGN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, URGN is overvalued; if below, it's undervalued.

Historical Valuation

Urogen Pharma Ltd (URGN) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -4.21. The fair price of Urogen Pharma Ltd (URGN) is between NaN to NaN according to relative valuation methord.

Relative Value

Fair Zone

NaN-NaN

Current Price：23.47

Fair

-15.17

-20.83

EV/EBITDA

Urogen Pharma Ltd. (URGN) has a current EV/EBITDA of -20.83. The 5-year average EV/EBITDA is -4.72. The thresholds are as follows: Strongly Undervalued below -12.56, Undervalued between -12.56 and -8.64, Fairly Valued between -0.80 and -8.64, Overvalued between -0.80 and 3.12, and Strongly Overvalued above 3.12. The current Forward EV/EBITDA of -20.83 falls within the Strongly Undervalued range.

-24.55

EV/EBIT

Urogen Pharma Ltd. (URGN) has a current EV/EBIT of -24.55. The 5-year average EV/EBIT is -4.89. The thresholds are as follows: Strongly Undervalued below -14.21, Undervalued between -14.21 and -9.55, Fairly Valued between -0.22 and -9.55, Overvalued between -0.22 and 4.44, and Strongly Overvalued above 4.44. The current Forward EV/EBIT of -24.55 falls within the Strongly Undervalued range.

5.29

Urogen Pharma Ltd. (URGN) has a current PS of 5.29. The 5-year average PS is 4.33. The thresholds are as follows: Strongly Undervalued below 0.53, Undervalued between 0.53 and 2.43, Fairly Valued between 6.22 and 2.43, Overvalued between 6.22 and 8.12, and Strongly Overvalued above 8.12. The current Forward PS of 5.29 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Urogen Pharma Ltd. (URGN) has a current P/OCF of 0.00. The 5-year average P/OCF is -3.56. The thresholds are as follows: Strongly Undervalued below -13.51, Undervalued between -13.51 and -8.53, Fairly Valued between 1.42 and -8.53, Overvalued between 1.42 and 6.40, and Strongly Overvalued above 6.40. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

237.69

P/FCF

Urogen Pharma Ltd. (URGN) has a current P/FCF of 237.69. The 5-year average P/FCF is 7.00. The thresholds are as follows: Strongly Undervalued below -92.97, Undervalued between -92.97 and -42.98, Fairly Valued between 56.98 and -42.98, Overvalued between 56.98 and 106.97, and Strongly Overvalued above 106.97. The current Forward P/FCF of 237.69 falls within the Strongly Overvalued range.

Urogen Pharma Ltd (URGN) has a current Price-to-Book (P/B) ratio of -9.51. Compared to its 3-year average P/B ratio of -3.52 , the current P/B ratio is approximately 170.14% higher. Relative to its 5-year average P/B ratio of -0.53, the current P/B ratio is about 1693.32% higher. Urogen Pharma Ltd (URGN) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -22.17%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -27.95% , the current FCF yield is about -100.00% lower.

-9.51

P/B

Median3y

-3.52

Median5y

-0.53

-12.91

FCF Yield

Median3y

-22.17

Median5y

-27.95

Competitors Valuation Multiple

The average P/S ratio for URGN's competitors is 0.00, providing a benchmark for relative valuation. Urogen Pharma Ltd Corp (URGN) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 9.04%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of URGN increased by 120.38% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -3.72 to -6.78.

The secondary factor is the Margin Expansion, contributed 29.18%to the performance.

Overall, the performance of URGN in the past 1 year is driven by P/E Change. Which is more unsustainable.

9.04%

25.20M → 27.48M

Revenue Growth

29.18%

-93.93 → -121.34

Margin Expansion

82.16%

-3.72 → -6.78

P/E Change

120.38%

10.65 → 23.47

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Urogen Pharma Ltd (URGN) currently overvalued or undervalued?

What is Urogen Pharma Ltd (URGN) fair value?

URGN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Urogen Pharma Ltd (URGN) is between NaN to NaN according to relative valuation methord.

How does URGN's valuation metrics compare to the industry average?

What is the current P/B ratio for Urogen Pharma Ltd (URGN) as of Dec 17 2025?

As of Dec 17 2025, Urogen Pharma Ltd (URGN) has a P/B ratio of -9.51. This indicates that the market values URGN at -9.51 times its book value.

What is the current FCF Yield for Urogen Pharma Ltd (URGN) as of Dec 17 2025?

As of Dec 17 2025, Urogen Pharma Ltd (URGN) has a FCF Yield of 0.00%. This means that for every dollar of Urogen Pharma Ltd’s market capitalization, the company generates 0.00 cents in free cash flow.

What is the current Forward P/E ratio for Urogen Pharma Ltd (URGN) as of Dec 17 2025?

As of Dec 17 2025, Urogen Pharma Ltd (URGN) has a Forward P/E ratio of -15.17. This means the market is willing to pay $-15.17 for every dollar of Urogen Pharma Ltd’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Urogen Pharma Ltd (URGN) as of Dec 17 2025?

As of Dec 17 2025, Urogen Pharma Ltd (URGN) has a Forward P/S ratio of 0.00. This means the market is valuing URGN at $0.00 for every dollar of expected revenue over the next 12 months.

URGN Valuation